# GenrAb

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genrab

- Industry: Biotechnology
- Headquarters: Dallas, US
- Website: www.genrab.com
- Total disclosed funding: $5.6M
- Latest round: Seed (Apr 22, 2025)
- Investors on record: 4

## About

GenrAb is a biotechnology company focused on developing neuroprotective monoclonal antibodies that target neurological disorders, utilizing advanced technology to harness the immune system's therapeutic potential.GenrAb specializes in creating innovative therapies for neurological care, particularly through monoclonal antibodies. The company is headquartered in Dallas, US, and has completed a total of one deal. It recently raised USD 5.6 mn in a Seed round led by Actium Group on April 22, 2025, bringing the total amount raised to USD 5.6 mn. The founder's history is not detailed in the provided information.GenrAb specializes in the development of neuroprotective monoclonal antibodies (mAbs) aimed at addressing the unmet needs in neurological care. Their core product offerings focus on harnessing the power of the human immune system to create therapies that prevent disease progression in various neurological disorders. The flagship candidate, TGM-010, targets a conserved neurodegenerative pathway and has shown promising preclinical results in reducing disability. With the use of their proprietary Antibody Gene Signature (AGS) technology, GenrAb has identified over 400 potentially therapeutic fully-human mAbs that leverage naturally occurring neuroprotective mechanisms. These products are primarily intended for use in patients suffering from neurological disorders and are expected to undergo clinical trials across various global markets, including North America and Europe.GenrAb's revenue structure is predicated on partnerships and collaborations within the biotechnology and pharmaceutical sectors, focusing on business-to-business transactions. The company engages with research institutions, pharmaceutical companies, and healthcare providers to facilitate the development and eventual commercialization of its neuroprotective therapies. Although specific pricing details are not disclosed, the transaction framework typically involves milestone payments, research funding, and licensing agreements associated with the development of their flagship mAb TGM-010 and other candidates. These partnerships aim to bring innovative treatments to market, ultimately benefiting patients with neurological disorders while generating revenue through collaborative efforts and potential future sales of their advanced therapeutic products.In April 2025, GenrAb raised USD 5.6 mn in Seed funding, which will be utilized to accelerate the development of its lead neuroprotective antibody candidate, TGM-010. The company is also planning to expand its clinical trials into new markets, specifically targeting regions in North America and Europe by late 2025.

## Funding rounds

- Seed, Apr 22, 2025, $5.6M — Actium Group, Green Park & Golf Ventures, Salem Partners Advisors, Research Bridge Partners

## Investors

- Actium Group (https://capitalatlas.ai/funds/actium-group) — Seed
- Green Park & Golf Ventures (https://capitalatlas.ai/funds/green-park-golf-ventures) — Seed
- Salem Partners Advisors — Seed
- Research Bridge Partners (https://capitalatlas.ai/funds/research-bridge-partners) — Seed